This is a standard operational partnership with no disclosed financial terms — no immediate revenue or earnings impact. Monitor future quarterly filings for any mention of revenue contribution from this collaboration, but no near-term catalyst is expected.
Price Chart
Executive Summary
Fortrea announced a collaboration with Omico, Australia's leading precision oncology screening organization, to accelerate biomarker-driven oncology clinical trials. The partnership combines Fortrea's global CRO expertise with Omico's PrOSPeCT program and its database of over 23,000 consented patients to improve site selection and patient recruitment in Australia. This is a routine service collaboration with no disclosed financial terms, deal value, or revenue impact.
Key Facts
- Fortrea and Omico announced a collaboration to accelerate precision oncology research in Australia
- Omico's PrOSPeCT program is Australia's largest cancer genomics initiative with over 23,000 consented patients and referrals from more than 1,600 clinicians
- No financial terms, deal value, or revenue guidance were disclosed
- Fortrea has more than 50 oncology physicians on staff and thousands of operational professionals
Financial Impact
No financial terms disclosed; collaboration is non-exclusive and operational in nature
Risk Factors
- No financial terms disclosed — revenue contribution, if any, is uncertain
- Collaboration is non-exclusive and does not guarantee future business wins
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3386887 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 3d ago | Press Release | $23.92 | awaiting T+1 | — | $23.82 (−0.44%) |
Oct 19, 2026 6d ago | Press Release | $22.78 $24.06 | ▲ +5.62% | ▲ +5.09% | $23.82 (+4.54%) |
Oct 5, 2026 21d ago | Press Release | $21.11 $20.78 | ▼ −1.56% | ▼ −2.11% | $23.82 (+12.81%) |
Sep 30, 2026 25d ago | 8-K | $19.40 $20.00 | ▲ +3.09% | ▲ +2.35% | $23.82 (+22.76%) |
Sep 10, 2026 6w ago | Press Release | $17.20 $17.41 | ▲ +1.22% | ▲ +1.67% | $23.82 (+38.46%) |
Sep 10, 2026 6w ago | 8-K | $17.02 $17.20 | ▲ +1.06% | ▲ +0.21% | $23.82 (+39.92%) |
Sep 2, 2026 7w ago | Press Release | $18.36 $18.62 | ▲ +1.42% | ▲ +0.37% | $23.82 (+29.71%) |
Aug 22, 2026 9w ago | Institutional Cluster | $18.31 $18.27 | ▼ −0.22% | ▼ −0.54% | $23.82 (+30.07%) |
Aug 7, 2026 11w ago | Insider Cluster | $18.99 $19.52 | ▲ +2.79% | ▲ +3.11% | $23.82 (+25.41%) |
Aug 6, 2026 11w ago | Insider Cluster | $18.43 $18.99 | ▲ +3.04% | ▲ +3.07% | $23.82 (+29.22%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers